FDA.reportPublic FDA data

antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection

RxCUI
2055659
RxNorm name
antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection
Display name
antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection
Full name
antihemophilic factor (recombinant), PEGylated-aucl 1 UNT Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:27

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125661JiviAntihemophilic factor (recombinant), PEGylated-aucl351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
f04e5bd5-d7e2-453b-a407-2616d81a695dantihemophilic factor (recombinant), PEGylated-aucl 1 UNT InjectionPSN13These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 201820260302
f04e5bd5-d7e2-453b-a407-2616d81a695dantihemophilic factor (recombinant), PEGylated-aucl 1 UNT InjectionSCD13These highlights do not include all the information needed to use JIVI safely and effectively. See full prescribing information for JIVI. JIVI ® [antihemophilic factor (recombinant), PEGylated-aucl] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 201820260302